FDA grants accelerated approval to Lilly's oral GLP-1 pill for obesity
Orforglipron becomes an oral small-molecule option in a market so far dominated by injectable incretins from Lilly and Novo Nordisk.
DO
By Daniel Okafor · Regulatory Correspondent
Apr 1 03:00 ETSource: AP News
The wire
- 01The FDA approved Eli Lilly's oral GLP-1 weight-loss drug for obesity under a speeded-up review pathway, according to the AP report.
- 02An oral incretin changes supply, storage and dispensing logistics for pharmacies and telehealth operators that have built workflows around injectables.
- 03Label details, pricing and launch supply were not laid out in the report; uptake will depend on coverage decisions and how the pill is positioned against injectable options.
From the source
Read at apnews.comFDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity